Delivering Next Generation Genetic Therapeutics

GenEdit is transforming the delivery of gene therapies
and enable the next generation of non-viral,
gene editing-based therapeutics

 

Mission

GenEdit is an innovative biotechnology company seeking to revolutionize gene therapy and gene editing enabled by its proprietary nanoparticle delivery technology.

SCIENCE

GenEdit’s key technology is based on successfully engineering the individual components of the CRISPR system to develop the first comprehensive delivery system for CRISPR-based therapeutics. This novel approach which includes both proprietary engineering and novel nanoparticles, enables safer delivery options with more improved efficiency in not only gene knockout therapies but, more importantly, in gene repair.

 
GenEdit_NanoGalaxy_v2.jpg

GENEDIT HAS THE OPPORTUNITY

To develop genetic therapeutics
for more diverse sets of genetic diseases
and significantly increase the market potential of gene editing-based therapeutics.

ABOUT
GENEDIT

GenEdit has roots at the University of California, Berkeley and officially launched in 2016. Since then, the team has developed its proprietary polymer nanoparticle library, establishing initial proof of concept by delivering CRISPR-Cas9 and gene editors to target tissues, leading to publications in key journals including Nature Biomedical Engineering (Duchenne Muscular Dystrophy, 2017) and Nature Biomedical Engineering (Autism, 2018), Nature Communications (CRISPR/Cas12a, 2018).

 

Landing_Image_3.jpg